chemical powder Semaglutide Somaglutide Semeglutide White loose powder Human API

Appetite regulation
Semaglutide mimics the natural hormone GLP-1, which is produced in the gut and plays a key role in regulating appetite and food intake. By activating the GLP-1 receptors in the brain, semaglutide helps reduce feelings of hunger, leading to decreased calorie intake.

Delayed gastric emptying
Semaglutide slows down the rate at which food leaves the stomach and enters the small intestine, a process known as delayed gastric emptying. This delayed gastric emptying leads to a prolonged sense of fullness and satiety, further reducing food intake.

Glucose-dependent insulin secretion
Semaglutide enhances the secretion of insulin in a glucose-dependent manner, meaning it increases insulin release only when blood glucose levels are elevated. This helps to improve blood sugar levels and reduce the risk of hypoglycemia (low blood sugar).

Glucagon suppression
Glucagon is a hormone that is produced by the pancreas and plays a key role in regulating blood sugar levels by stimulating the liver to release glucose into the bloodstream. By suppressing the release of glucagon, semaglutide helps to lower blood sugar levels in individuals with diabetes. By reducing glucagon levels, semaglutide further helps to maintain healthy blood sugar levels, which is particularly beneficial for individuals with type 2 diabetes.

Energy expenditure and lipid metabolism
Semaglutide has been shown to increase energy expenditure and promote fat burning, leading to reductions in body weight and improvements in body composition. It may also have a positive impact on lipid metabolism, contributing to favorable changes in cholesterol and triglyceride levels.

The largest clinical trial studying semaglutide in adults showed an average weight loss of about 15% of initial body weight over 68 weeks (almost 16 months). Over the same length of time in another study, adolescents lost 15% of their initial body weight on average.

There are several oral weight loss pills available. Oral weight-loss medications tend to be less expensive than the injectable options. But you may not lose as much weight.

Phentermine: Phentermine (Adipex-P) is a popular oral weight-loss medication that has been around since 1959. It's approved for short-term use (a few weeks), and it's inexpensive. However, it's possible to develop a tolerance to the medication where it's no longer working for you. Plus, it's a controlled substance.

Qsymia: Phentermine is also available in combination with topiramate under the brand name Qsymia. Compared to phentermine alone, Qsymia can be taken for a longer period of time. Study results have shown average weight loss ranging from about 5% (at lower doses) to around 10% (at higher doses).

Contrave: Contrave (bupropion / naltrexone) is another medication used for weight loss. One study showed that people taking Contrave in combination with diet and exercise lost an average of about 9% of their baseline body weight after 56 weeks. Contrave also has several drug interactions to consider.

Semaglutide for weight loss is approved to be used in adults and children 12 years of age and older based on their body mass index (BMI) and the presence of certain health conditions.

You may see some weight loss in the 4 weeks of semaglutide treatment, but the full effect can take several months. After 68 weeks, adults lost about 35 lbs (15.9 kg) in studies, on average.

Your doctor will slowly increase your dose when you start treatment to help lessen stomach side effects like nausea and diarrhea. It typically takes about 17 weeks to reach your final maintenance dose of semaglutide.

Studies conducted by the manufacturer over 68 weeks show that, on average, adults using semaglutide lost about 35 lbs (15.9 kg), or about 15% of their body weight. In contrast, 31% of people using a placebo (inactive treatment) lost about 6 lbs (2.7 kg), or about 2.5% of their body weight.

In children 12 years and older, semaglutide reduced their body mass index (BMI) by 16.1% after 68 weeks compared to a 0.6% reduction in the placebo group. Plus, the BMI was reduced by at least 5% in 77% of children receiving semaglutide compared to 20% receiving a placebo.

We believe in the power of science-backed treatments, and Semaglutide is no exception. This medication targets the intricate interplay of hormones, neurotransmitters, and neural circuits that regulate appetite and metabolism.

Enhancing Satiety and Appetite Control
Receptors are abundant in areas of the brain responsible for appetite regulation. Semaglutide activates these receptors, leading to increased feelings of fullness and reduced hunger. This means you're more likely to make mindful food choices and consume fewer calories, a fundamental aspect of successful weight loss.

Slowing Gastric Emptying
Semaglutide goes beyond appetite suppression by slowing down the rate at which your stomach empties. This results in a prolonged feeling of satiety after meals, curbing your cravings and helping you resist the urge to overeat.

Modulating Reward Pathways
Semaglutide's influence extends to the brain's reward centers, which are responsible for the pleasurable sensations associated with food. By targeting these neural circuits, Semaglutide helps dampen the allure of high-calorie, indulgent foods, making it easier to stick to your nutritional plan.

The application of semaglutide in patients with elevated hematocrit and hemoglobin levels introduces a nuanced layer to its therapeutic spectrum, especially considering the implications of these hematological parameters on cardiovascular health. High hematocrit and hemoglobin levels, indicative of polycythemia, can increase blood viscosity, thereby elevating the risk of thrombosis and vascular complications.

The impact of semaglutide on hematocrit and hemoglobin levels is a topic of emerging interest, driven by the understanding that metabolic disorders can influence various hematological parameters. Preliminary data suggest that GLP-1 receptor agonists, including semaglutide, may have a neutral or potentially beneficial effect on these levels. However, the mechanisms underlying these effects are not fully elucidated and warrant further investigation. Potential explanations include semaglutide's role in improving metabolic control, which may indirectly influence erythropoiesis and red blood cell turnover.

Given the cardiovascular risks associated with high hematocrit and hemoglobin levels, the use of semaglutide in such populations requires careful consideration. It involves assessing the potential benefits of metabolic improvement against the theoretical risks related to blood viscosity and thrombosis. Clinicians must adopt a vigilant approach, involving regular monitoring of hematological parameters and cardiovascular signs and symptoms, to promptly address any adverse trends.

The management of patients with elevated hematocrit and hemoglobin levels on semaglutide therapy also emphasizes the importance of a holistic treatment strategy. This strategy may include lifestyle interventions, such as hydration and smoking cessation, and the use of aspirin or other antithrombotic agents in patients at high risk of vascular events. The decision to initiate or continue semaglutide treatment in this context should be based on a comprehensive risk-benefit analysis, taking into account the individual patient's cardiovascular risk profile and the potential impact of improved metabolic control on overall health.

Fujian Genohope Biotech Ltd was established in 2019, It was co-founded by New Hope  Hosencare Brothers  and Taiwan Genovior Biotech Corporation. The company is located in the national "Cross-Strait Biotechnology and Health and Medical Industry Cooperation Zone" in Putian City, Fujian Province. The company has 260 employees, and in 2023, the company was selected as a Specialized in special innovative enterprises in Fujian Province.

The company focuses on High potency polypeptide API/solution, and sells polypeptide API/solution and preparation production services to the global market. The company covers a total area of 55 mu, with a total construction area of about 70,000 square meters, and has built about 800 square meters of R & D center, 1,000 square meters of  quality control center and 3,300 square meters of GMP production workshop. At present, 13 production  lines have been built, including 7 production lines for the preparation of recombinant peptide API and fully synthetic peptide API and 6 lines for injections. In addition, the company also has a large anti-tumor injection workshop, a small multi-purpose injection workshop, a large multi-purpose injection workshop. The construction and operation management of the production line meet the regulatory requirements of the global drug market and meet the double registration and declaration of China and the United States. Also can meet the customer registration and sales at home and abroad.

Product superiority：

At present, the company's main products are Semaglutide, Tirzepatide, Retatrutide, cosmetic medicine microspheres, collagen. In particular, the company has the advantage of mature 2 processes preparation of Semaglutide API, Semaglutide API registered in the US FDA (DMF No. : 040957),Tirzepatide API registered in the US FDA (DMF No. : 040503),

Semaglutide API has the following three characteristics: low price, high quality, and large production capacity (tonnage). Tirzepatide API is well received favourable reviews in the pharmaceutical industry of polypeptide .

Our Certificate

Q: What does semaglutide do to your body?

Q: Who cannot take semaglutide?